SPSylvya Pasca

Sylvya Pasca

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sylvya Pasca has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure 1 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    BETi pretreatment sensitizes tumor cells to pIC-induced inflammation. A, Experimental setup for BETi pretreatment and pIC transfection of tumor cells. B, Protein abundance of phosphorylated IRF3 and (C) TBK1 in A375 cells after 72 hours of JQ1 or DMSO pretreatment and pIC transfection for 24 hours assessed by Western blot. n = 5 biological replicates. A representative Western blot is depicted in (D). E, Expression heatmap of selected genes from qPCR after 72 hours of JQ1 treatment and subsequent pIC transfection for 24 hours in ANRU, (F) KADA, and (G) A375. Data are represented as mean fold change from DMSO. n = 3 biological replicates/cell line. H, Bar plot displaying gene expression of selected genes from G (log2 fold change from DMSO). I, CXCL10 and (J) IFNβ concentration in supernatants from treated A375, ANRU, and BEHA cells. n = 3 biological replicates/cell lines. K, Cell surface expression of HLA-I was assessed by flow cytometry after 48 hours of pIC stimulation preceded by either DMSO or JQ1 treatment in four melanoma cell lines. n ≥ 3 biological replicates/cell line. L, Representative histogram plot for A375 from (G). M, Cell surface expression of HLA-I assessed by flow cytometry after 48 hours of pIC stimulation preceded by either DMSO or JQ1 treatment in the colorectal cancer cell line COLO320. n = 3 biological replicates. N, Cell surface expression of HLA-I in A375 after JQ1/pIC in the presence or absence of an IFNα/βR1-blocking antibody (2 µg/mL). n = 3 biological replicates. O, HLA-I expression in ANRU cells upon concomitant treatment with JQ1 and/or nontargeting control siRNA (NTC) or siRNA targeting TLR3, RIG-I, or MDA-5, prior to transfection with pIC. n = 3 biological replicates. Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons. geoMFI, geometric mean fluorescence intensity. [A, Created in BioRender. Wickstrom, S. (2026) https://BioRender.com/npulau2.]

  • Open Access

    Figure 3 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Prolonged BET inhibition rewires antiviral pathways and depletes tumors of negative regulators of dsRNA-sensing pathways. A, Schematic overview of the RNA-seq experiment related to (B) and (C). B, Cytoscape network of significantly regulated genes by JQ1 compared with DMSO related to the GO term “Regulation of type I interferon.” Node color represents upregulated (red) or downregulated (blue) genes in JQ1 versus DMSO. C, Network of significantly regulated genes by JQ1 + IFNγ compared with IFNγ-treated cells related to the GO term “Cellular response to type I interferon.” Node color represents upregulated (red) or downregulated (blue) genes in JQ1 + IFNγ versus IFNγ. D, Heatmap of selected genes from qPCR after 48 hours of JQ1-, IFNγ- or JQ1 + IFNγ-treated KADA, (E) ANRU, and (F) A375. Data are represented as mean fold change from DMSO. n = 2 biological replicates/cell line. G, Gene expression of negative regulators of antiviral signaling after 24, 48, and 72 hours of JQ1 treatment in A375. Mean of n = 3 technical replicates. H, Cell surface expression of HLA-I was assessed by flow cytometry after A375 cells were subjected to pretreatment with JQ1 alone for either 24, 48, or 72 hours and/or stimulation with pIC for 48 hours. n = 3 biological replicates. I, CXCL10 and IFNλ1 concentrations were measured by ELISA after pIC transfection of cells pretreated with nontargeting control siRNA (NTC), NLRX1-targeting siRNAs (siNLRX1), or JQ1. n = 2 biological replicates. J, HLA-I expression in A375 and ANRU cells after NTC, siNLRX1, or JQ1 pretreatment and pIC transfection. n = 3 biological replicates. K, HLA-I expression of A375 and ANRU upon JQ1 and/or pIC in the presence or absence of a JAK1/2 inhibitor (ruxolitinib, 2 µmol/L). L, Representative flow cytometry histogram from A375-treated cells in (K). Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons. geoMFI, geometric mean fluorescence intensity. [A, Created in BioRender. Wickstrom, S. (2026) https://BioRender.com/xoxbyk3.]

  • Open Access

    Data from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Intratumoral signaling via the cytosolic double-stranded RNA (dsRNA) receptors RIG-I and MDA-5 enhances antitumor immunity and can overcome resistance to cancer immunotherapy. Although bromodomain extraterminal (BET) proteins are established epigenetic drivers of immune escape mechanisms, their role in regulating RIG-I–like receptor (RLR) signaling remains undefined. Therefore, we investigated the role of BET proteins in modulating innate antiviral responses to cytosolic dsRNA in tumor cells and how BET inhibition combined with dsRNA stimulation influences tumor immunogenicity and recognition by T cells. To address this, human tumor cell lines were treated with the BET inhibitor (BETi) JQ1 and transfected with the synthetic viral dsRNA analog poly(I:C) (pIC) to stimulate innate antiviral signaling. We found that BET inhibition synergistically amplifies dsRNA-induced immunogenicity, as indicated by enhanced cytokine and chemokine production, JAK–STAT signaling, antigen presentation, and immunogenic cell death. Combined treatment of melanoma cells with JQ1 and pIC resulted in a marked, synergistic enhancement of recognition by autologous tumor-specific CD8+ tumor-infiltrating lymphocytes and maturation of dendritic cells. Furthermore, an antiviral gene signature induced by pIC and enhanced by JQ1 correlated with immune infiltration and improved survival in larger patient cohorts across different types of cancer. Overall, our findings demonstrate that targeting BET proteins in tumor cells strongly potentiates dsRNA-induced antiviral responses and suggest that combining BETis with RLR agonists offers a pharmacologic strategy to enhance antitumor T-cell responses and improve the clinical efficacy of cancer immunotherapies.

  • Open Access

    Figure 2 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Transcriptional analysis reveals an enhanced proinflammatory and antiviral state upon combined JQ1/pIC treatment. A, Experimental setup for RNA-seq experiment. B, Volcano plot of differentially expressed genes (DEG) between pIC- and DMSO-treated ANRU tumor cells. C, Dot plot of the top 10 enriched GOs in pIC versus DMSO. D, Volcano plot of DEGs between JQ1/pIC- and pIC-treated ANRU tumor cells. E, Dot plot of the top 10 enriched GOs in JQ1/pIC versus pIC. F, Venn diagrams displaying the number of significantly upregulated genes between various treatment groups from the GO term “Response to virus.” G, Heatmap displaying the expression of genes in DMSO-, JQ1-, pIC-, and JQ1/pIC-treated cells found differentially expressed between pIC versus DMSO and JQ1/pIC versus pIC in GO terms “Response to virus” (23 genes). H, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment plots of pathways enriched in JQ1/pIC versus pIC. I, Heatmap of selected genes from KEGG pathways displayed in (H). J, IFNλ1 concentration in supernatants from treated A375, ANRU, and BEHA cells. n = 3 biological replicates/cell line. Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons. geoMFI, geometric mean fluorescence intensity. [A, Created in BioRender. Wickstrom, S. (2026) https://BioRender.com/b31gu8z.]

  • Open Access

    Figure 5 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Enhanced activation of neoantigen/TAA-specific CD8+ TILs using JQ1 and/or pIC treatment in cancer cells. A, Proportion of CD8+ MART-1pos (MART-1+) T cells and CD8+ NUP210pos (NUP210+) T cells in CD3+ ANRU TIL. B, Representative flow cytometry plots for IFNγ+CD107a+ T cells gated on MART-1pos TIL and NUP210pos TIL after coculture with treated ANRU tumor cells. C, Frequency of IFNγ+CD107a+ MART1pos and (D) IFNγ+CD107a+ NUP210pos T cells after coculture with treated ANRU tumor cells. n = 3 biological replicates. E, Frequency of IFNγ+TNFα+ for MART-1pos T cells and (F) IFNγ+TNFα+ NUP210pos T cells. n = 3 biological replicates. G, Proportion of IFNγ+, TNFα+, IFNγ−TNFα−, and IFNγ+TNFα+ MART-1pos TILs after coculture with treated ANRU tumor cells. n = 3 biological replicates. Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons.

  • Open Access

    Figure 6 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Enhanced dsRNA signaling through BETi promotes ICD and DC maturation. A, GO enrichment plots from JQ1/pIC versus pIC comparison in ANRU related to the GO terms “Positive regulation of programmed cell death” and “Positive regulation of apoptotic process.” B, Representative flow cytometry gating for dead cells, calreticulin, and HSP90 in treated A375 cells. C, Proportion of dead cells in KADA, ANRU, A375, BEHA, and COLO320 cells after JQ1 and/or pIC treatment. n ≥ 3 biological replicates/cell line. D, Bar graphs indicating the frequency of calreticulinhi (n = 4 biological replicates) and (E) HSP90hi (n = 3 biological replicates) A375 cells after JQ1 and/or pIC treatment. F, Experimental setup for DC experiments. G, Representative histogram plots of CD86 in DCs after exposure to treated A375 cells or A375 SN. H, Expression of CD80, CD86, HLA-I, HLA-II, CD1a, and PD-L1 displayed as bar graphs or (I) heatmap after exposure of iDCs to treated A375 cells for 48 hours. Data are presented as fold change to iDCs exposed to DMSO-treated A375 cells. n = 4 biological replicates. J, Expression of CD80, CD86, HLA-I, HLA-II, CD1a, and PD-L1 displayed as bar graphs or (K) heatmap after exposure of iDCs to treated A375 SN for 48 hours. Data are presented as fold change to iDCs exposed to control A375 SN. n = 4 biological replicates. L, Correlation plot between the expression of the DC_S3 signature (Luca and colleagues) and the antiviral signature in TCGA patients with melanoma. M, Correlation analysis of antiviral signature, ICD signature, and 3 single-cell RNA-seq DC signatures in the TCGA cohort of patients with melanoma and (N) in all patients with cancer from TCGA. Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons. geoMFI, geometric mean fluorescence intensity. [F, Created in BioRender. Wickstrom, S. (2026) https://BioRender.com/dbfr9mh.]

  • Open Access

    Figure 7 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Antiviral signaling correlates with improved immunotherapy efficacy and survival of patients with cancer. A, t-distributed stochastic neighbor embedding (t-SNE) plot displaying the inverse correlation between the expression of the antiviral signature and the immune resistance signature in melanoma cells, quantified in (B). C, Heatmap showing the level of correlation between single-cell RNA-seq signatures of immune resistance/exclusion and our antiviral signature in TCGA patients with melanoma. D, Expression of the antiviral signature predicts survival of patients with melanoma in the TCGA cohort. Kaplan–Meier (KM) curves are stratified by high (top 20%), low (bottom 20%), or moderate (remainder) expression of the antiviral signature. The number of subjects at risk is indicated at the bottom of the KM curves for four time points. P, COX regression P value. E, Expression of the antiviral signature is enhanced in ANRU upon JQ1 pretreatment. F, Survival analysis using JQ1/pIC downregulated, upregulated, or up–down gene signatures in TCGA patients with melanoma. G, Expression of the antiviral signature correlates with improved OS in immunotherapy-treated melanoma and (H) pan-cancer patients. KM curves are stratified by high (top 20%) and low (bottom 20%) expression of the antiviral signature.

  • Open Access

    Supplementary Figure S1 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Gating strategies used in flow cytometry for tumor cells, T cell and DC stainings.

  • Open Access

    Figure 4 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Tumor cells treated with JQ1 promote activation of cytotoxic TILs in melanoma when combined with dsRNA agonist. A, Bar graph displaying IFNγ secretion measured by ELISA after coculture of autologous TILs with KADA (n = 6 biological replicates), (B) ANRU (n = 4 biological replicates), and (C) BEHA (n = 4 biological replicates) tumor cells after treatment with DMSO, JQ1, pIC, or JQ1/pIC, in the presence or absence of an HLA-I–blocking antibody. D, Representative flow cytometry plots from coculture of TILs with treated ANRU tumor cells gated on live CD3+CD8+ and IFNγ+CD107a+ (bottom) or IFNγ+TNFα+ (top) T cells. E, Violin plots display the frequency of IFNγ+CD107a+ in CD8+ T cells in KADA and (F) ANRU TILs. G, Violin plots display the frequency of IFNγ+TNFα+ in CD8+ T cells in KADA and (H) ANRU TIL. I, Mean IFNγ expression in live CD3+CD8+IFNγ+ KADA and (J) ANRU TILs. Error bars represent mean ± standard deviation. Statistical analysis was performed using paired one- or two-way ANOVA with Holm–Šidák correction for multiple comparisons. P values <0.05 are indicated above the relevant comparisons. geoMFI, geometric mean fluorescence intensity.

  • Open Access

    Supplementary Figure S13 from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition

    by Lucas Baldran-Groves, Rok Žiberna, Marc-Antoine Gerault, Mireia Cruz De Los Santos, Adela Kiessling, Sylvya Pasca, Nooshin Khoshdoozmasouleh, Andreas Post, Andreas Lundqvist, Stina Wickström, et al.

    Supplementary data from transcriptomic analysis of TGCA melanoma cohort.